A new biomarker in the differential diagnosis of epileptic seizure: Neurogranin

Basit Öğe Kaydı
dc.authoridAtis, Seref Emre/0000-0002-5094-6000
dc.authoridKaraaslan, Edip Burak/0000-0002-0127-7744
dc.authoridFERHATLAR, MEHMET ESAT/0000-0002-3497-8547
dc.authoridSenturk, Mucahit/0000-0002-5504-273X
dc.contributor.authorKalkan, Asim
dc.contributor.authorDemirel, Ahmet
dc.contributor.authorAtis, Seref Emre
dc.contributor.authorKaraaslan, Edip Burak
dc.contributor.authorFerhatlar, Mehmet Esat
dc.contributor.authorSenturk, Mucahit
dc.date.accessioned2024-09-29T15:54:55Z
dc.date.available2024-09-29T15:54:55Z
dc.date.issued2022
dc.departmentKarabük Üniversitesien_US
dc.description.abstractAim: The aim of this study was to determine the level of serum NGRN in epilepsy patients presenting at the Emergency Department with complaints of an epileptic seizure, and to thus evaluate the utility of this biomarker in the differentiation of epilepsy and PNES patients from each other. Material methods: The study included patients aged >18 years who had experienced an epileptic seizure or were experiencing an epileptic seizure proven with EEG. All patients with brain disease of structural or infectious cause were excluded from the study (dementia, stroke, intracranial mass, meningitis, encephalitis, Creutzfeldt-Jacobs disease, abscess, etc). Patients were also excluded if they had traumatic brain injury or a severe systemic disease such as sepsis, which was thought to impair brain blood flow. The control group was formed of completely healthy volunteers. Results: Evaluation was made of a total of 49 patients, comprising 19 (38.78%) males and 30 (61.22%) females, and a control group of 53 healthy volunteers comprising 28 (52.83%) males and 25 (47.17%) females. The serum neurogranin value was median 184.16 ng/dl (range: 110.1-1172.98) in the patient group and 97.90 ng/dl (range: 73.71-282. 11) in the control group. The serum neurogranin value was determined to be statistically significantly higher in the patient group than in the control group (p < 0.005). Conclusion: The differential diagnosis of ES from PNES remains a challenging situation for emergency service physicians. Based on the findings of this study, it can be said that the serum NRGN level is high in patients who have experienced an epileptic seizure. Therefore, this new biomarker can be considered for use in the differential diagnosis of epileptic seizure and PNES. (c) 2022 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.ajem.2022.02.010
dc.identifier.endpage150en_US
dc.identifier.issn0735-6757
dc.identifier.issn1532-8171
dc.identifier.pmid35152125en_US
dc.identifier.scopus2-s2.0-85124288604en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage147en_US
dc.identifier.urihttps://doi.org/10.1016/j.ajem.2022.02.010
dc.identifier.urihttps://hdl.handle.net/20.500.14619/4356
dc.identifier.volume54en_US
dc.identifier.wosWOS:000797601400028en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherW B Saunders Co-Elsevier Incen_US
dc.relation.ispartofAmerican Journal of Emergency Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkersen_US
dc.subjectEpilepsiaen_US
dc.subjectSeizuresen_US
dc.subjectPsychogenic nonepileptic seizuresen_US
dc.subjectNeurograninen_US
dc.subjectBiomarkersen_US
dc.subjectEpilepsiaen_US
dc.subjectSeizuresen_US
dc.subjectPsychogenic nonepileptic seizuresen_US
dc.subjectNeurograninen_US
dc.titleA new biomarker in the differential diagnosis of epileptic seizure: Neurograninen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu